Overview

About this study

The purpose of this study is to evaluate the effectiveness and mechanism of action of Losartan in the treatment of coarctation of aorta. 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

- B/S1 hypertension; SBP 120-139 average based on 3 office measurements.

- COA Repair prior to age 10

- No residual COA; Based on mean doppler COA gradient < 20mmHg within past 12 months

Exclusion Criteria:

- Currently on beta blocker (BB) therapy

- Pregnancy/lactating

- eGFR < 30

- Hyperkalemia (serum potassium > 5.5mmol/L)

- Severe Aortic or Mitral valve stenosis or regurgitation

- Epicardial CAD diagnosis

- Received antihypertensive medications within the past year

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 2/21/2024. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Alexander Egbe, M.B.B.S., M.P.H.

Open for enrollment

Contact information:

Adult Congenital Research Program

(507) 293-2565

RSTACHDRESPRG@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20558886

Mayo Clinic Footer